Management of neuropsychiatric symptoms in long-term care residents with Parkinson’s disease: a retrospective cohort study
Herrmann N, Marras C, Fischer HD, Wang X, Anderson GM, Rochon PA. Drugs Aging. 2013; 30(1):19-22. Epub 2012 Nov 28.
Publications
CNODES: the Canadian Network for Observational Drug Effect Studies
Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, Lelorier J, Levy A, Martens PJ, Paterson JM, Platt RW, Sketris I, Teare G; Canadian Network for Observational Drug Effect Studies (CNODES). Open Med. 2012; 6(4):134-40. Epub 2012 Oct 30.
Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study
Juurlink DN, Gomes T, Guttmann A, Hellings C, Sivilotti ML, Harvey MA, Mamdani MM. Clin Toxicol. 2012; 50(5):390-5. Epub 2012 Apr 27.
Psychotropic medications and motor vehicle collisions in patients with dementia
Rapoport MJ, Herrrmann N, Molnar F, Rochon PA, Juurlink DN, Zagorski B, Seitz D, Morris JC, Redelmeier DA. J Am Geriatr Soc. 2008; 56(10):1968-70. Epub 2008 Oct 1.
How complete are drug history profiles that are based on public drug benefit claims?
Paterson JM, Suleiman A, Hux JE, Bell C. Can J Clin Pharmacol. 2008; 15(1):e108-16. Epub 2008 Feb 19.
Impact of a fluoroquinolone restriction policy in an elderly population
Mamdani M, McNeely D, Evans G, Hux J, Oh P, Forde N, Conly J. Am J Med. 2007; 120(10):893-900.
Case selection for statins was similar in two Canadian provinces: BC and Ontario
Paterson JM, Carney G, Anderson GM, Bassett K, Naglie G, Laupacis A; BC-Ontario Pharmacosurveillance for Decision-making Collaborative. J Clin Epidemiol. 2007; 60(1):73-8. Epub 2006 Sep 7.
Using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative
Paterson JM, Laupacis A, Bassett K, Anderson GM; BC-Ontario Pharmacosurveillance for Decision-Making Collaborative. Health Aff. 2006; 25(5):1436-43.
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada
Austin PC, Mamdani MM. Circulation. 2005; 112(9):1296-300. Epub 2005 Aug 22.
The changing landscape for COX-2 inhibitors: a summary of recent events
Mamdani M. Healthc Q. 2005; 8(2):24-6.